News Releases

Nearly half of the approximately 17 million cancer survivors today have battled either breast or prostate cancer, and Black and Hispanic patients with these cancers are at an increased risk for developing cardiovascular disease.

Researchers at Penn Medicine have identified more genetic mutations that strongly predispose younger, otherwise healthy women to peripartum cardiomyopathy (PPCM), a rare condition characterized by weakness of the heart muscle that begins sometime during the final month of pregnancy through five months after delivery.

A retrospective study led by researchers from Penn Medicine found that with MitraClip for treatment of secondary mitral regurgitation (MR), a heart disease associated with problems in the left ventricle, there was no negative effect of having a slightly smaller mitral valve opening as long as there was good reduction of the mitral regurgitation.

A new study from researchers at the Perelman School of Medicine at the University of Pennsylvania found significant disparities in the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of drugs proven to treat type 2 diabetes, with usage remaining low with Black, Asian, and lower-income groups despite an increase in overall usage for patients with type 2 diabetes.

Even though the use of rhythm control strategies for treating Paroxysmal Atrial Fibrillation (AF), a common abnormal heart rhythm, have increased overall in the United States, patients from racial and ethnic minority groups and those with lower income were less likely to receive rhythm control treatment - often the preferred treatment - according to new research from the Perelman School of Medicine at the University of Pennsylvania.

Scientists in the Perelman School of Medicine at the University of Pennsylvania have uncovered the molecular causes of a congenital form of dilated cardiomyopathy (DCM), an often-fatal heart disorder.

Cardiac rehabilitation is a therapy that combines guided exercise along with heart-healthy lifestyle education that can be life-saving for the majority of people who have had a major cardiac event, such as a heart attack. However, it is underutilized in the United States, with many hospitals referring just 20 percent or fewer of their eligible patients, largely because the referral process can be cumbersome.

It isn’t a death sentence if a COVID-19 patient suffers a cardiac arrest while getting treatment for the virus in the hospital, according to new research that contradicts reports from early on in the pandemic.